Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

- Numax Achieves Primary Endpoint Among High-Risk Infants Versus Current Standard of Care and Shows Reduction of Medically Attended Outpatient RSV- Related Lower Respiratory Infections -

TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced positive results from a large prospective trial conducted for prevention of respiratory syncytial virus (RSV). The trial compared motavizumab, the investigational monoclonal antibody (MAb) also known as Numax(R), with Synagis(R) (palivizumab), the standard of care for preventing RSV hospitalization in high-risk infants. In the Phase 3 study involving 6,635 pre-term infants at high risk for RSV, with a primary endpoint of non- inferiority, motavizumab demonstrated overall 26-percent fewer RSV hospitalizations compared with Synagis (p<0.01 for non-inferiority). Additionally, motavizumab demonstrated a statistically significant 50 percent reduction in the incidence of RSV-specific medically attended outpatient lower respiratory infections (LRIs) (p<0.01) compared with Synagis. These findings were presented today in a poster entitled, Phase 3 Trial of Motavizumab, an Enhanced Potency RSV-Specific MAb for the Prevention of Serious RSV Disease in High-Risk Infants, at the Pediatric Academic Societies' Annual Meeting in Toronto, Canada.

"As RSV continues to be the leading cause of lower respiratory tract infections in infants in the United States, we are very encouraged by the results of this Phase 3 trial, which suggest that motavizumab may help to reduce the chance that our most vulnerable babies will have serious RSV disease," said Edward M. Connor, M.D., chief medical officer and executive vice president. "Data from the study showed that motavizumab was statistically superior to Synagis for the secondary endpoint of outpatient medically attended LRI caused by RSV, and thus may reduce the overall burden of RSV disease compared to the current stan
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/25/2014)... N.C. , Oct. 24, 2014 ... provide Medical Affairs leaders with a forum for ... The consortium has developed a mechanism for creating ... where leaders discuss key findings from the Medical ... has completed the analysis for the first roundtable ...
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
(Date:10/22/2014)... Investor-Edge has initiated coverage on the following ... Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), Threshold ... Inc. (NASDAQ: IDRA ), and Merrimack Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,419.48, up 2.40%, the Dow Jones Industrial Average ...
Breaking Medicine Technology:Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
(Date:10/25/2014)... Everett, WA (PRWEB) October 25, 2014 ... their insulation has ‘gone bad’ need wonder no more. ... that homeowners should watch out for when it ... Bad insulation, according to the article released by Clean ... emphasize for homeowners that any insulation that has deteriorated, ...
(Date:10/25/2014)... blood supply to an arm or a leg before heart ... according to a new study. "During heart surgery ... to be able to operate on it. After some time ... produce energy because it doesn,t get oxygen. When we shut ... an arm or a leg, the body prepares for an ...
(Date:10/25/2014)... 2014 (HealthDay News) -- A large influx of international ... to avoid tens of thousands of deaths from the ... predict. Using a specially designed mathematical model, ... outbreak in just one densely populated county of hard-hit ... of Monrovia. The researchers said that if international ...
(Date:10/22/2014)... At a time when the national concussion conversation ... all levels, the UPMC Sports Medicine Concussion Program ... two powerful messages are lost: Concussions can be treated, ... recoveries every day. , In striving to shift the ... UPMC and the Concussion Program are unveiling the online ...
(Date:10/22/2014)... Ann Arbor, MI (PRWEB) October 22, 2014 ... Association of Schools of Allied Health Professions (ASAHP) Conference ... Isabel Founder and CEO will participate in a panel ... Training and Practice. , Isabel Healthcare provides a diagnostic ... assist in improving the diagnosis skills of students and ...
Breaking Medicine News(10 mins):Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
... Study highlights:, -- Drug-eluting stents showed improved ... -- No excess adverse events were found ... Nov. 11 Drug-eluting stents,reduced the risk of ... with bare-metal stents in the largest observational comparison,researchers ...
... ORLEANS, Nov. 11 A veteran medical,correspondent ... Howard L.,Lewis Achievement Award for excellence in ... of Freemont, Calif., was honored for "his ... economic,political, ethical and cultural implications of cardiovascular ...
... new technique to study genetic changes that can lead to ... of Nottingham has received 15,000 from the charity Breast Cancer ... by the country,s top breast cancer experts in a recent ... identify the many undiscovered genes thought to be involved in ...
... University of Exeter have found that a walk of ... of exercise in helping people manage dependencies on nicotine ... the first time, newly-published research shows that the same ... days of abstinence, 25 regular chocolate eaters were asked ...
... Unwavering Corporate and Employee Commitment to CourionCares,Philanthropy Program ... Mass., Nov. 11 Courion(R) Corporation,leaders in access ... corporate citizenship program, has raised more,than $100,000 in ... years.,Courion,s eighth annual charity auction held on Friday, ...
... Nov. 11 Misonix, Inc.,(Nasdaq: MSON ), a ... in Europe is used for the ablation of ... announced plans to,release first quarter fiscal year 2009 ... A. McManus, President and Chief,Executive Officer and Richard ...
Cached Medicine News:Health News:Drug-Eluting Stents Beat Bare Metal Stents in Diabetics 2Health News:Drug-Eluting Stents Beat Bare Metal Stents in Diabetics 3Health News:Drug-Eluting Stents Beat Bare Metal Stents in Diabetics 4Health News:New technique to study the genetics of breast cancer 2Health News:Brisk walk could help chocoholics stop snacking 2Health News:Courion Exceeds $100,000 Charitable Giving Milestone with Eighth Annual Employee Fundraiser 2Health News:Courion Exceeds $100,000 Charitable Giving Milestone with Eighth Annual Employee Fundraiser 3Health News:Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern 2
0.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish....
Two 2.75 mm long tips separated 1 mm with 1 x 2 teeth. Serrated handle with dull finish....
1 x 2 teeth and 5.5 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm....
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish....
Medicine Products: